← Eichor
Study identifier: NCT07263230 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Safety and Efficacy of Roflumilast Foam in HS

Condition: Hidradenitis Suppurativa (HS)  ·  Sponsor: Beth Israel Deaconess Medical Center

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study investigates the efficacy of topical roflumilast foam in patients with HS.

This description comes directly from the study's public registry record.

Talk to the study team

Martina Porter, MD  ·  6176675834  ·  clears@bidmc.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Beth Israel Deaconess Medical CenterBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07263230